Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

BACKGROUND: Studies have shown that cigarette smokers constitute a substantial proportion of patients with acute coronary syndromes (ACS) and have platelet-rich coronary thrombi. We characterized the influence of smoking status on outcome of patients with ACS without persistent ST-segment elevation and tested the hypothesis that selective inhibition of the platelet glycoprotein IIb/IIIa receptor with eptifibatide would improve outcomes among cigarette smokers. METHODS: The study population included patients enrolled in the PURSUIT trial (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) with known smoking status presenting with ischemic chest pain

Full Text

Duke Authors

Cited Authors

  • Hasdai, D; Holmes, DR; Criger, DA; Topol, EJ; Califf, RM; Wilcox, RG; Paolasso, E; Simoons, M; Deckers, J; Harrington, RA

Published Date

  • March 2000

Published In

Volume / Issue

  • 139 / 3

Start / End Page

  • 454 - 460

PubMed ID

  • 10689260

International Standard Serial Number (ISSN)

  • 0002-8703

Digital Object Identifier (DOI)

  • 10.1016/s0002-8703(00)90089-9


  • eng

Conference Location

  • United States